OrthoPediatrics Corp. (NASDAQ:KIDS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

OrthoPediatrics Corp. (NASDAQ:KIDS) has been given a consensus rating of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $34.1429.

Several research analysts have commented on the stock. BTIG Research dropped their price objective on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Citigroup restated a “market outperform” rating on shares of OrthoPediatrics in a report on Friday, August 8th. JMP Securities set a $35.00 price target on shares of OrthoPediatrics and gave the company a “market outperform” rating in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th.

OrthoPediatrics Trading Down 2.0%

Shares of NASDAQ KIDS opened at $20.49 on Wednesday. OrthoPediatrics has a 1-year low of $16.59 and a 1-year high of $33.14. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The business’s 50 day moving average is $21.05 and its two-hundred day moving average is $21.94. The stock has a market capitalization of $513.68 million, a P/E ratio of -11.45 and a beta of 1.06.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, August 5th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06. The firm had revenue of $61.08 million during the quarter, compared to analysts’ expectations of $61.40 million. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. OrthoPediatrics has set its FY 2025 guidance at EPS. As a group, research analysts expect that OrthoPediatrics will post -0.93 EPS for the current year.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The stock was purchased at an average cost of $19.41 per share, with a total value of $98,525.16. Following the purchase, the chief financial officer owned 213,065 shares of the company’s stock, valued at approximately $4,135,591.65. The trade was a 2.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 31.80% of the company’s stock.

Institutional Trading of OrthoPediatrics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp boosted its stake in shares of OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after purchasing an additional 644 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in OrthoPediatrics by 12.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock valued at $342,000 after buying an additional 1,753 shares in the last quarter. Invesco Ltd. boosted its position in OrthoPediatrics by 12.1% in the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock valued at $452,000 after buying an additional 1,986 shares during the period. Finally, American Century Companies Inc. grew its stake in OrthoPediatrics by 12.5% in the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after acquiring an additional 3,828 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.